MedPath

Special Use - Results Surveillance on Long-term Use With Wegovy®

Conditions
Obesity
Interventions
Registration Number
NCT06283667
Lead Sponsor
Novo Nordisk A/S
Brief Summary

The purpose of the study is to investigate the safety and effectiveness of Wegovy® in patients with obesity disease under real-world clinical practice in Japan. Participants will get Wegovy® as prescribed by the study doctor. The study will last for about 4 years. Participant will be in the study for about 2 years (104 weeks).

Detailed Description

Not available

Recruitment & Eligibility

Status
ENROLLING_BY_INVITATION
Sex
All
Target Recruitment
1000
Inclusion Criteria
  • Signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol)

  • The decision to initiate treatment with commercially available Wegovy® has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study

  • Male or female, no age limitation

  • Diagnosis of obesity disease; with either hypertension, dyslipidaemia or type 2 diabetes, insufficiently controlled with diet and exercise therapies, and should meet either of:

    1. Body mass index (BMI)* greater than or equal to 27 kilograms per meter square (kg/m^2) with two or more obesity-related comorbidities**, or
    2. BMI* greater than or equal to 35 kg/m^2
  • Participant who has never been exposed to Semaglutide or who started treatment with Wegovy® within the past 4 weeks at registration

    • BMI calculation will be based on height and body weight recorded in the enrolment form of electronic case report form (eCRF) at enrolment.

      • Definition of obesity-related comorbidities are in accordance with Japan Student Services Organization (JASSO) guideline 3: (1) impaired glucose tolerance, (2) dyslipidaemia, (3) hypertension, (4) hyper-uricemia/gout, (5) coronary artery disease, (6) cerebral infarction, (7) non-alcoholic fatty liver disease, (8) menstrual disorder/infertility, (9) obstructive sleep apnoea syndrome/obesity-hypoventilation syndrome, (10) locomotory disease or (11) obesity-related kidney disease.
Exclusion Criteria
  • Previous participation in this study. Participation is defined as having given informed consent in this study
  • Treatment with any investigational drug within 30 days prior to baseline (Visit 1)
  • Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation
  • A history of hypersensitivity to any ingredients of this drug
  • Diabetic ketoacidosis, diabetic coma, pre-coma or type 1 diabetes mellitus [The treatment with insulin is mandatory. It is not appropriate to use this drug]
  • In emergency cases such as severe infections and surgery in patients with type 2 diabetes [It is desirable to control blood glucose with insulin; therefore, administration of this drug is not appropriate]
  • Pregnant or possibly pregnant female
  • Female who plans to become pregnant within 2 months

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Wegovy®SemaglutidePatients with obesity treated with Wegovy® (semaglutide) once weekly under real-world clinical practice conditions in Japan.
Primary Outcome Measures
NameTimeMethod
Number of Adverse Reactions (ARs)From baseline (week 0) to end of study (week 104)

Measured as count of events

Secondary Outcome Measures
NameTimeMethod
Change in BMI (Body Mass Index)From baseline (week 0) to end of study (week 104)

Measured in kilogram per meter square (kg/m\^2)

Change in body weight after treatment discontinuationFrom treatment discontinuation after at least 12 weeks to end of study (week 104)

Measured as percent (%)

Number of Serious Adverse Reactions (SARs)From baseline (week 0) to end of study (week 104)

Measured as count of events

Number of serious adverse events (SAEs)From baseline (week 0) to end of study (week 104)

Measured as count of events

Change in body weight (Percent (%))From baseline (week 0) to end of study (week 104)

Measured as percent (%)

Change in body weight (Kilograms (Kg))From baseline (week 0) to end of study (week 104)

Measured in kilograms (Kg)

Change in waist circumferenceFrom baseline (week 0) to end of study (week 104)

Measured in centimeters (cm)

Number of Adverse Events (AEs)From baseline (week 0) to end of study (week 104)

Measured as count of events

Trial Locations

Locations (110)

Nagoya City University Hospital_Obesity Treatment Center

🇯🇵

Aichi, Japan

Kameda Medical Center_Diabetes and Endocrinology

🇯🇵

Chiba, Japan

Mikannohana Clinic

🇯🇵

Ehime, Japan

National Hospital Organization Fukuokahigashi Medical Center

🇯🇵

Fukuoka, Japan

Fukuoka Kieikai Hospital_Diabetes and obesity centre

🇯🇵

Fukuoka, Japan

Chuno Kosei Hospital_Endocrinology and Diabetes

🇯🇵

Gifu, Japan

Murakami Memorial Hospital

🇯🇵

Hiroshima, Japan

Kagoshima University Hospital_Diabetes and Endocrinology

🇯🇵

Kagoshima, Japan

Showa University Fujigaoka Hospital_Internal Medicine

🇯🇵

Kanagawa, Japan

Yokohama City Minato Red Cross Hospital

🇯🇵

Kanagawa, Japan

Scroll for more (100 remaining)
Nagoya City University Hospital_Obesity Treatment Center
🇯🇵Aichi, Japan

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.